Monoclonal antibody · Antagonist of interleukin-17A (IL17A) · developed by Novartis Pharms
Secukinumab is a human IgG1 monoclonal antibody that binds the pro-inflammatory cytokine interleukin-17A and blocks its interaction with the IL-17 receptor, reducing inflammatory signaling. It is studied in psoriasis and related immune-mediated inflammatory diseases.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02786186 | N/A | Psoriasis | Completed | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Psoriasis
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →